Cas:1353980-07-0 [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride manufacturer & supplier

Chemical Name:[1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride

CAS.NO:1353980-07-0

Synonyms:[1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride

Molecular Formula:C₁₄H₂₃ClN₂O

Molecular Weight:270.79822

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride Use and application,[1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride technical grade,usp/ep/jp grade.

Related News: In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride manufacturer “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride supplier In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride vendor “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. [1-(4-Methoxy-benzyl)-piperidin-3-yl]-Methyl-aMine hydrochloride factory In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.